Edwards touts multi-trial heart valve data

Edwards Lifesciences (NYSE:EW) yesterday released results from 3 trials of its surgical heart valves designed for treating aortic valve disease, touting positive clinical results from studies of over 2,000 patients. Data from the trials was presented during late-breaking sessions at the American Association for Thoracic Surgery’s 96th annual meeting this week, the company said. “Edwards is proud to lead the innovation of heart valve therapies to address a broad range of patient needs around the world, and these compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments. We are committed to expanding our surgical heart valve portfolio with meaningful innovations and by continuing to work in partnership with surgeons to meet the needs of patients who suffer from a variety of heart valve diseases,” surgical heart valve therapy corporate veep Bernard Zovighian said in a press release. Edwards presented 1-year data from the 674-patient Commence pivotal trial of its surgical aortic valve featuring Resilia tissue, touting no cases of structural valve deterioration, valve thrombosis or nonstructural valve dysfunction. “The early clinical results with the new valve with Resilia tissue in this multicenter, international FDA trial are encouraging and set a high benchmark for surgical aortic valve replacement. The Resilia tissue has the potential to create a new class of surgical tissue valves th...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Edwards Lifesciences Source Type: news